Kicking off in Chicago on the 31st May, the 2024 American Society of Clinical Oncology’s Annual Meeting - known as ASCO - welcomed more than forty thousand healthcare professionals through
Novel therapies, often with expensive price tags and finite patient populations, require strategic new positioning if they are to have maximum positive impact.
With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh